Survey Indicates Weight Loss Drugs Are Lowering U.S. Obesity Rates

There is a growing trend among Americans to utilize injectable medications like Wegovy and Zepbound for weight management, contributing to a reduction in the nation’s substantial obesity prevalence.

According to the Gallup National Health and Well-Being Index, the surge in the use of injectable treatments for obesity is playing a significant role in lowering obesity figures.

The national obesity rate has decreased to 37% of adult Americans this year, having previously peaked at 39.9% three years back, as reported by the survey findings.

The survey highlighted a noteworthy rise in the number of Americans using weight loss drugs such as semaglutide, available under brand names like Ozempic and Wegovy, as well as tirzepatide, sold as Zepbound and Mounjaro. Over the last 18 months, this figure more than doubled from 5.8% in February 2024 to 12.4% among respondents. These medications, known as GLP-1 agonists, made their debut in the U.S. market in 2021.

GLP-1 agonists have made a significant impact on obesity treatment in America by affecting the brain and hormonal processes to alleviate hunger and slow food digestion. Despite years of rising obesity rates through various diets and health strategies, these drugs offer new hope.

The survey suggests a slow but ongoing change in these trends. The use of GLP-1 medications is particularly prevalent in individuals aged 40 to 64, who showed a larger decline in obesity rates. Specifically, obesity rates among those aged 50 to 64 saw a 5 percentage point drop to 42.8%. Additionally, women appear to use these medications more frequently than men, experiencing greater weight loss outcomes.

While these drugs represent a crucial advance for obesity sufferers, the availability of these treatments is still not universal. Harvard University obesity expert Dr. Fatima Cody Stanford notes that access is expected to narrow.

Dr. Stanford mentions, "The positive correlation in coverage is about to reverse," as many private insurers, responsible for many of her patients’ coverage, will halt support for GLP-1 drugs next year. Without insurance coverage, the cost of these injections may reach $500 monthly for patients. Despite efforts by drug manufacturers to develop potentially cheaper oral alternatives, these solutions could remain financially challenging for many people.